Full 12 months Results Revenues for the year ended December 31, 2013 were $9.7 million, weighed against revenues of $1.0 million in 2012. Total operating expenditures for 2013 were $29.6 million, compared with total operating expenses of $7.7 million in 2012. Research and development expenses improved by $5.1 million and general and administrative expenses increased by $0.9 million. The increase in research and development expenses was mainly due to the completion of the 9 month inhalation dog study in 2013 and the preparation for the start of the Pulmaquin Stage 3 clinical trials which led to higher costs in agreement manufacturing and testing along with higher clinical trial expenses.By the real way, wasn’t it the FDA that urged Americans never to purchase pharmaceuticals from Canada or Mexico because they could not be safe? Evidently swallowing ground-up machine parts from a tablet factory in Puerto Rico is definitely safer than buying quality-managed pharmaceuticals from Canada, in the event that you ask the FDA. Again Then, maybe they’re simply trying to safeguard the U.S. Pharmaceutical monopoly. The supplements are dangerous also if they are designed correctlyWhat these outrageous quality control complications bring to light may be the reality that pharmaceuticals are harmful to your wellbeing on two levels: 1st, there’s the chance of harm or loss of life due to the drugs themselves, even though they are properly developed and consumed.